Joshua Nelson Gustine, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Waldenstrom Macroglobulinemia | 42 | 2024 | 1073 | 6.320 |
Why?
|
Myeloid Differentiation Factor 88 | 21 | 2024 | 587 | 3.450 |
Why?
|
Receptors, CXCR4 | 13 | 2021 | 727 | 2.730 |
Why?
|
Pyrazoles | 15 | 2024 | 2009 | 1.930 |
Why?
|
Pyrimidines | 15 | 2024 | 3028 | 1.710 |
Why?
|
Adenine | 18 | 2024 | 987 | 1.430 |
Why?
|
Piperidines | 18 | 2024 | 1656 | 1.170 |
Why?
|
Immunoglobulin M | 8 | 2020 | 1527 | 1.130 |
Why?
|
Amyloidosis | 2 | 2023 | 817 | 1.030 |
Why?
|
Point Mutation | 2 | 2021 | 1595 | 0.640 |
Why?
|
Hydrolases | 1 | 2019 | 147 | 0.600 |
Why?
|
Mycobacterium | 1 | 2019 | 251 | 0.570 |
Why?
|
Blood Viscosity | 1 | 2017 | 124 | 0.560 |
Why?
|
Cell Wall | 1 | 2019 | 425 | 0.510 |
Why?
|
Mutation | 21 | 2024 | 30052 | 0.510 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 106 | 0.500 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2020 | 621 | 0.490 |
Why?
|
Immune System | 1 | 2020 | 796 | 0.490 |
Why?
|
Immunoglobulin Light Chains | 2 | 2023 | 285 | 0.410 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 5671 | 0.310 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2917 | 0.300 |
Why?
|
Lymphoma, B-Cell | 2 | 2022 | 940 | 0.230 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5671 | 0.230 |
Why?
|
B-Lymphocytes | 2 | 2016 | 4758 | 0.220 |
Why?
|
Treatment Outcome | 13 | 2024 | 64680 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5305 | 0.180 |
Why?
|
Melphalan | 1 | 2022 | 420 | 0.180 |
Why?
|
Inflammation | 1 | 2020 | 10773 | 0.180 |
Why?
|
Humans | 50 | 2024 | 761504 | 0.180 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7407 | 0.170 |
Why?
|
Aged | 27 | 2022 | 169289 | 0.160 |
Why?
|
Aged, 80 and over | 18 | 2021 | 58976 | 0.150 |
Why?
|
Colony Count, Microbial | 1 | 2019 | 330 | 0.150 |
Why?
|
Survival Analysis | 7 | 2021 | 10090 | 0.150 |
Why?
|
Mycobacterium bovis | 1 | 2019 | 147 | 0.150 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2020 | 1405 | 0.150 |
Why?
|
Mycobacterium smegmatis | 1 | 2019 | 126 | 0.150 |
Why?
|
Survival Rate | 7 | 2021 | 12725 | 0.150 |
Why?
|
Disease-Free Survival | 5 | 2019 | 6814 | 0.150 |
Why?
|
Middle Aged | 28 | 2021 | 220895 | 0.150 |
Why?
|
Bone Marrow | 4 | 2021 | 2911 | 0.150 |
Why?
|
Microbial Viability | 1 | 2019 | 238 | 0.140 |
Why?
|
Macrophage Activation | 1 | 2020 | 553 | 0.140 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5127 | 0.140 |
Why?
|
Transplantation, Autologous | 1 | 2022 | 2115 | 0.140 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2018 | 242 | 0.140 |
Why?
|
Plasmapheresis | 1 | 2017 | 206 | 0.130 |
Why?
|
Paracrine Communication | 1 | 2018 | 277 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2019 | 3617 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6484 | 0.130 |
Why?
|
MAP Kinase Signaling System | 2 | 2024 | 1486 | 0.130 |
Why?
|
DNA Mutational Analysis | 2 | 2021 | 4111 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 11742 | 0.120 |
Why?
|
Antineoplastic Agents | 4 | 2018 | 13639 | 0.120 |
Why?
|
Quinazolinones | 1 | 2016 | 221 | 0.120 |
Why?
|
Phagocytosis | 1 | 2020 | 1528 | 0.120 |
Why?
|
Drug Synergism | 1 | 2019 | 1755 | 0.120 |
Why?
|
von Willebrand Factor | 1 | 2018 | 673 | 0.110 |
Why?
|
Stem Cell Transplantation | 1 | 2022 | 1600 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2018 | 617 | 0.110 |
Why?
|
Drug Resistance | 1 | 2019 | 1596 | 0.110 |
Why?
|
Male | 28 | 2024 | 360804 | 0.110 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12463 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1386 | 0.110 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2018 | 625 | 0.110 |
Why?
|
Purines | 1 | 2016 | 607 | 0.110 |
Why?
|
Prognosis | 8 | 2024 | 29625 | 0.110 |
Why?
|
Female | 28 | 2024 | 392644 | 0.100 |
Why?
|
Virus Replication | 1 | 2020 | 2435 | 0.100 |
Why?
|
Adult | 18 | 2021 | 221177 | 0.100 |
Why?
|
Retrospective Studies | 9 | 2023 | 80636 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1880 | 0.090 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2200 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2018 | 1264 | 0.090 |
Why?
|
Monocytes | 1 | 2020 | 2570 | 0.090 |
Why?
|
Antitubercular Agents | 1 | 2019 | 1375 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2017 | 2825 | 0.090 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39106 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3639 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 3065 | 0.080 |
Why?
|
Neutrophils | 1 | 2020 | 3767 | 0.070 |
Why?
|
Oxygen | 1 | 2019 | 4227 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2022 | 14605 | 0.060 |
Why?
|
Macrophages | 1 | 2020 | 5769 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2091 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2021 | 9177 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10194 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-hck | 1 | 2022 | 46 | 0.050 |
Why?
|
Cell Survival | 2 | 2024 | 5791 | 0.050 |
Why?
|
Risk Factors | 3 | 2018 | 74206 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13506 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 16981 | 0.040 |
Why?
|
Paraproteins | 1 | 2020 | 38 | 0.040 |
Why?
|
Signal Transduction | 3 | 2020 | 23445 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2022 | 2898 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2022 | 535 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2017 | 5146 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2020 | 329 | 0.040 |
Why?
|
Pneumocystis carinii | 1 | 2018 | 72 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2020 | 328 | 0.030 |
Why?
|
Boron Compounds | 1 | 2018 | 182 | 0.030 |
Why?
|
von Willebrand Diseases | 1 | 2018 | 132 | 0.030 |
Why?
|
Prospective Studies | 4 | 2021 | 54425 | 0.030 |
Why?
|
Histocytochemistry | 1 | 2016 | 698 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 523 | 0.030 |
Why?
|
Glycine | 1 | 2018 | 663 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17904 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 39967 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 678 | 0.030 |
Why?
|
Plasma Cells | 1 | 2017 | 599 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1870 | 0.030 |
Why?
|
Genotype | 2 | 2017 | 12990 | 0.030 |
Why?
|
Age of Onset | 1 | 2018 | 3305 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 2020 | 0.020 |
Why?
|
Dexamethasone | 1 | 2018 | 1948 | 0.020 |
Why?
|
NF-kappa B | 1 | 2018 | 2490 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2045 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1886 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2735 | 0.020 |
Why?
|
Incidence | 2 | 2016 | 21353 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2568 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8529 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3802 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13255 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6863 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5789 | 0.020 |
Why?
|
Biopsy | 1 | 2016 | 6766 | 0.010 |
Why?
|
Genomics | 1 | 2020 | 5821 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8002 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7396 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2017 | 12974 | 0.010 |
Why?
|
DNA Methylation | 1 | 2016 | 4398 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22176 | 0.010 |
Why?
|
Apoptosis | 1 | 2018 | 9486 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18395 | 0.010 |
Why?
|
Genetic Variation | 1 | 2016 | 6567 | 0.010 |
Why?
|
Immunotherapy | 1 | 2016 | 4652 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 8547 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15936 | 0.010 |
Why?
|